China's Pipeline Goes Global: The Licensing Wave Rewriting Big Pharma's Deal Math
Chinese biotechs signed licensing deals worth more than 60 billion dollars in the first quarter of 2026 alone. The wave is repricing how multinational pharma sources its pipeline, and the deal structures are telling a more nuanced story than the headline numbers.